MedTrace Logo

A Trial of Dehydroepiandrosterone (DHEA) Treatment for in Vitro Fertilization (IVF)

NCT00419913 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2008-04-02

No results posted yet for this study

Summary

Our long term goal is to elucidate the role of DHEA on follicular dynamics in the human ovary and to better understand the interaction of DHEA supplementation with other treatments for ovulation induction, especially among older reproductive age women.

The specific hypothesis behind the proposed research is that DHEA is a regulator of follicular dynamics acting in the early pre-gonadotropin dependent stage of initial primordial follicle recruitment and growth.

Conditions

Interventions

DIETARY_SUPPLEMENT

Dehydroepiandrosterone

DHEA 25 mg tid

Sponsors & Collaborators

  • Foundation for Reproductive Medicine

    collaborator OTHER

  • Center for Human Reproduction

    lead OTHER

Principal Investigators

  • David Barad, MD · Center for Human Reproduction

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2007-07-31
Completion
2008-01-31

Countries

  • United States
  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00419913 on ClinicalTrials.gov